Drug Trial Radar · NCT04987489
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Mar 28, 2022
Primary completion
Sep 3, 2025
Study completion Sep 24, 2025
Sponsor
- Lead sponsor
- Forma Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
Conditions
- Sickle Cell Disease
- Thalassemia
Interventions
Etavopivat tabletsDrug
Etavopivat 400 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts A: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion historyTime frame: 12 weeks
- Cohorts B: Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion historyTime frame: 12 weeks
- Cohort C: Hemoglobin response rate at Week 12 (increase of ≥ 1.0 g/dL from baseline)Time frame: 12 weeks
Locations
32 sites in 6 countries. Site status is shown where the registry gives one.
TOI Clinical Research
Cerritos, California
[Legal] Children's Hospital Los Angeles
Los Angeles, California
University of Californ LA-UCLA
Los Angeles, California
UCSF Oakland Benioff ChildHosp
Oakland, California
[Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County
Orange, California
UCI Health
Orange, California
Children's National Health Hospital
Washington D.C., District of Columbia
Children's Hospital of Atlanta
Atlanta, Georgia
[Legal] Dr. Vince Clinical Research, LLC and Dr. Vince Clinical Research, P.A.
Detroit, Michigan
Weill Medical College of Cornell University
New York, New York
Duke University
Durham, North Carolina
East Carolina University
Greenville, North Carolina
[Legal] Children's Hospital Medical Center dba Cincinnati Children's
Cincinnati, Ohio
Children's Hosptl Philadelphia
Philadelphia, Pennsylvania
Master Centre for Canada
Mississauga, Ontario, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
University Health Network - Toronto General Hospital
Toronto, Ontario, Canada
CHU Sainte-Justine Mother and Child University Hospital
Montreal, Quebec, Canada
Cairo University
Cairo, Egypt
Abu El-Reesh El-Mounira Children University Hospital
Cairo, Egypt, Egypt
Galliera Hospital Centro Anemie Congenite
Genova, Italy
Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
AORN A. Cardarelli
Naples, Italy
A.O.U. Università Studi della Campania "Luigi Vanvitelli"
Naples, Italy
Chronic Care Center
Baabda, Lebanon
Hospital Nini
Tripoli, Lebanon
Sandwell and West Birmingham NHS Trust SCAT/ haematology
Birmingham, United Kingdom
Barts Health NHS Trust - The Royal London Hospital
London, United Kingdom
University College Hospital - University College London Hospitals NHS Foundation Trust
London, United Kingdom
Kings College London
London, United Kingdom
Hammersmith Hospital - London
London, United Kingdom
Manchester University NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.